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ABSTRACT   
BACKGROUND: The increasing incidence of oropharyngeal cancer in many developed 
countries has been attributed human papillomavirus type 16 (HPV16) infections. Recently, 
HPV16 E6 serology has been identified as a promising early marker for oropharyngeal cancer.  
Therefore, characterization of HPV16 E6 seropositivity among individuals without cancer is 
warranted.  METHODS: 4,666 controls were pooled from several studies of cancer and HPV 
seropositivity, all tested within the same laboratory.  HPV16 E6 seropositive controls were 
classified as having i) moderate seroreactivity (MFI ≥484 & <1000) or ii) high seroreactivity 
(MFI ≥ 1000). Associations of moderate and high HPV16 E6 seroreactivity with i) demographic 
risk factors; and seropositivity for ii) other HPV16 proteins (E1, E2, E4, E7 and L1) and iii) E6 
proteins from non-HPV16 types (HPV6, 11, 18, 31, 33, 45 and 52) were evaluated.  RESULTS: 
Thirty-two (0.7%) HPV16 E6 seropositive controls were identified; 17 (0.4%) with moderate and 
15 (0.3%) with high seroreactivity.  High HPV16 E6 seroreactivity was associated with former 
smoking (OR 5.5 [95%CI: 1.2-51.8]), and seropositivity against HPV16 L1 (OR 4.8, 95%CI: 
1.3-15.4); E2 (OR 7.7, 95%CI: 1.4-29.1); multiple HPV16 proteins (OR 25.3, 95%CI: 2.6-119.6 
for 3 HPV16 proteins beside E6) and HPV33 E6 (OR 17.7, 95%CI: 1.9-81.8).  No associations 
were observed for controls with moderate HPV16 E6 seroreactivity.  CONCLUSIONS: High 
HPV16 E6 seroreactivity is rare among individuals without diagnosed cancer and was not 
explained by demographic factors. Some HPV16 E6 seropositive individuals, especially those 
with seropositivity against other HPV16 proteins, may be on the path to an HPV-driven cancer. 
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INTRODUCTION 
A rapid increase in the incidence of oropharyngeal cancer has been reported in many parts of the 
world with a high development index (1-8), especially among men younger than 60 years of age 
(9).  This upsurge has been attributed to an increase in HPV-driven oropharyngeal cancers (7).  
In the US, incidence has increased by more than 200 percent over the past several decades (10).  
HPV16 infection alone accounts for approximately 90 percent of HPV-positive oropharyngeal 
cancers (11, 12) and is estimated to be responsible for at least 50% of oropharyngeal cancer 
cases in parts of the world with a high development index (10, 13, 14).   
Unlike cervical cancer, a precursor lesion for oropharyngeal cancer has yet to be identified, 
making early detection of oropharyngeal cancers difficult (15).  However, numerous case-control 
studies have shown that the presence of circulating HPV antibodies is strongly associated with 
cancer of the oropharynx (12, 16-24).  Recently, HPV16 E6 antibody positivity has been 
identified as a potentially promising marker for oropharyngeal cancer (25).  A prospective study 
conducted with prediagnostic sera found that 35% of patients with oropharyngeal cancer were 
seropositive for HPV16 E6 compared to only 0.6% of controls; for some of the patients these 
antibodies were present more than 10 years prior to diagnosis and were not associated with 
cancers at other head and neck cancer sites (25). 
Due to the high specificity of HPV16 E6 seropositivity for oropharyngeal cancer, this marker has 
the potential to be further developed into a screening tool for identifying high-risk individuals.  
Therefore, characterization of HPV16 E6 seropositivity within healthy individuals without 
diagnosed cancer is merited.  However, HPV16 E6 seropositivity is extremely rare among 
healthy individuals without cancer (<1%), making it difficult to adequately study (23-25).   
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To overcome this issue, we conducted a descriptive epidemiological analysis of pooled controls 
from several studies of cancer and HPV seropositivity whose samples were all tested within the 
same laboratory with a bridging panel that allowed for interpretation across studies (23-25).  The 
goals of this analysis were to investigate demographic and serologic factors associated with 
HPV16 E6 seropositivity among individuals without diagnosed cancer. 
METHODS 
Our analytic population consisted of 4,666 controls pooled from several large studies of HPV 
seropositivity; 3 studies of head and neck cancer and 1 study of anogenital cancers (23-26).  
Controls were pooled from i) two nested case-control investigations within the European 
Prospective Investigation Into Cancer and Nutrition (EPIC); one focused on head and neck 
cancer (n=1,599 controls) and one focused on HPV-driven anogenital cancers (n=718 controls) 
(25, 26); ii) 1 nested case-control investigation within the Prostate, Lung, Colorectal, and 
Ovarian Cancer Screening Trial (PLCO) (n=924 controls) (27); and iii) 1 case-control study, the 
Alcohol-Related Cancers and Genetic Susceptibility in Europe (ARCAGE) (n=1,425 controls) 
(23). 
Description of Study Populations and Participant Selection 
EPIC Cohort Study 
In brief, 521,330 individuals were recruited to the cohort between 1992 and 2000 from 10 
European countries, of whom 385,747 participants contributed a blood sample (28). Participants 
completed self-administered questionnaires on lifestyle factors and diet. Two control participants 
(one in Denmark) were randomly assigned for each patient with cancer (including head and neck 
and anogenital cancers) from appropriate risk sets consisting of all cohort participants alive and 
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free of cancer (except non-melanoma skin cancer) at the time of diagnosis (and hence, age) of 
the index case.  Additional study specific matching criteria are discussed below. 
 EPIC Head and Neck Study 
Matching criteria were: country, sex, date of blood collection (± 1 month, relaxed to ± 5 months 
for sets without available controls), and date of birth (±1 year, relaxed to ± 5 years for sets 
without available participants). The final study included 1,599 controls (25). 
EPIC Anogenital Study 
Matching criteria included: study center, sex, date of blood collection (± 3 months, relaxed to ± 6 
months for sets without available controls), and age at blood collection (± 3 months, relaxed to ± 
2 years for sets without available controls), fasting status, and where relevant, menopausal status, 
and postmenopausal hormone replacement therapy use, and menstrual cycle.  The final study 
included 718 controls (26). 
PLCO Cohort Study 
PLCO recruited approximately 155,000 55-74 year-olds from the general population during 
1993-2001 who had not been diagnosed previously with prostate, lung, colorectal, or ovarian 
cancer.  Blood (screening arm only), demographic and behavioral data were collected (29). 
Blood samples were obtained at baseline and five subsequent annual visits; the earliest available 
sample was used for this study.  For each case, four controls were randomly chosen from 
appropriate risk sets consisting of all cohort members alive and free of cancer (except non-
melanoma skin cancer) at the time (and hence age) of diagnosis of the index head and neck 
cancer case. Matching criteria were: year of entry into the study, year the material was collected, 
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study year of cancer diagnosis (for cases; the same year was used for the matched control), birth 
year, and smoking status (never, former, current) (26).  
ARCAGE Case-Control Study 
Briefly, 2,227 control subjects were recruited from 10 European countries during the period from 
2002 to 2005 using a standardized protocol in all centers (except France) (30).  All subjects 
underwent personal interviews to record lifestyle exposures; details are described elsewhere (30).  
Controls were recruited in each center and frequency matched for age, sex, and area of residence 
to cases with head and neck cancer. ARCAGE centers mainly used hospital controls to facilitate 
collection of blood samples, with the exception of the UK centers which used population-based 
controls randomly chosen from the same family medical practice list as the corresponding cases. 
Hospital controls were selected from the following diagnoses: endocrine and metabolic, skin, 
subcutaneous tissue and musculoskeletal, circulatory, nervous system diseases, genitourinary, 
gastro-intestinal, ear, eye and mastoid, plastic surgery cases and trauma patients (23).   
Harmonization of Covariates 
Given the variation between studies in how the covariates were ascertained, we were unable to 
create single unified definitions of smoking and alcohol consumption.  As a result, individuals 
were categorized according to study-specific definitions of smoking and alcohol consumption 
(Supplemental Table 1).  
Harmonization of Serologic Test Results  
Plasma (EPIC and ARCAGE) and serum (PLCO) samples were sent on dry ice to the German 
Cancer Research Center (DKFZ, Heidelberg, Germany) and testing was performed using 
multiplex assays (24, 31-33). Samples were analyzed for HPV16 antibodies to the major capsid 
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protein (L1), the early oncoproteins (E6, E7), and other early proteins (E1, E2, E4) with the 
exception of PLCO where seroreactivity against HPV16 E4 was not assessed.  Additionally, 
seroreactivity against the E6 protein from the following HPV types was also evaluated; HPV6, 
HPV11, HPV18, HPV31, HPV33, HPV45 and HPV52 with the exception of the EPIC anogenital 
study were seroreactivity against HPV52 was not assessed.  A bridging panel was included in all 
studies so that MFI values could be normalized to account for variations in the assay between 
studies (34). This bridging panel allowed us to apply the same standard MFI cutoff values for 
seropositivity across all three studies.  For HPV16 E6, two mutually exclusive categories of 
HPV16 E6 seroreactivity were created: i) moderate: MFI ≥ 484 and < 1000; and high: MFI ≥ 
1,000.   Previous work from our group showed that increasing the seropositivity cutoff of HPV16 
E6 from 484 to 1000 resulted in an increased specificity for oropharyngeal cancer without an 
associated decrease in sensitivity (25).   For the other HPV16 proteins the MFI cutoffs used to 
define seropositivity were: L1, 422; E1, 200; E2, 679; E4, 876; E6, 484; E7, 548.  For the E6 
proteins of non-HPV16 types the MFI cutoffs for seropositivity were: HPV6 E6, 500; HPV11, 
260; HPV18, 243; HPV31, 890; HPV33, 253; HPV35, 260; HPV45, 249; HPV52, 271.  
Statistical Analyses 
Characteristics of the control participants were evaluated overall and by study. The proportion of 
HPV16 E6 seropositive controls by demographic categories was computed for the pooled 
studies.  Demographic and serologic determinants of moderate and high HPV16 E6 
seroreactivity were evaluated through odds ratios (OR) and 95% confidence intervals (CI) 
calculated in univariate analyses by logistic regression. Demographic variables evaluated 
included: gender, age, world region, smoking status and alcohol consumption. Serologic 
variables evaluated included seroreactivity against: i) other HPV16 proteins (L1, E1, E2, E4, E7) 
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and ii) E6 proteins from non-HPV16 types (HPV6, HPV11, HPV18, HPV31, HPV33, HPV45 
and HPV52). 
RESULTS 
Participant Characteristics  
A total of 4,666 controls without diagnosed cancer were included in this analysis (Table 1); 1425 
(30.5%) individuals from ARCAGE; 2,317 (49.7%) from EPIC and 924 (19.8%) from PLCO.  
The majority of the controls were male (63.7%), 60 years of age or younger (59.6%) and ever 
alcohol drinkers (80.3%); smoking status appeared evenly distributed among the categories (i.e.: 
never, former, current). Small differences between studies were noted for gender, age and 
smoking status (Table 1).  
Demographic Determinants of HPV16 E6 Seropositivity 
HPV16 E6 seropositivity was rare.  Of the 4,666 pooled controls, a total of 32 individuals (0.7%) 
were seropositive for HPV16 E6.  Prevalence of HPV16 E6 seropositivity was similar by study; 
ARCAGE (0.8%), EPIC (0.6%) and PLCO (0.9%).  Of the 32 HPV16 E6 seropositive controls, 
17 (0.4%) were classified as having moderate HPV16 E6 seropositivity (MFI ≥ 484 and < 1000) 
and 15 (0.3%) were classified as having high HPV16 E6 seroreactivity (MFI ≥ 1000) (Table 2).   
Age, gender, smoking status and alcohol consumption did not elevate the odds of moderate or 
high HPV16 E6 seroreactivity.  Only former smoking was significantly associated with high 
HPV16 E6 seroreactivity, OR 5.5 (95% CI: 1.2-51.8).  No other significant associations for 
either moderate or high HPV16 E6 seroreactivity were observed (Table 2). 
Serologic Determinants of HPV16 E6 Seropositivity 
11 
 
Seroreactivity against HPV16 proteins, including L1, E1, E2, E4 or E7, was common. Similar 
seroprevalence for any of these proteins was observed among the HPV16 E6 seronegative and 
moderately HPV16 E6 seroreactive controls; 27.9% and 29.4%, respectively (Table 3).  No 
significant associations between moderate HPV16 E6 seroreactivity and seroreactivity against 
any of the other HPV16 proteins either individually or combined was observed.   
In contrast, prevalence of seroreactivity against 1 or more HPV16 proteins (L1, E1, E2, E4 or 
E7) in addition to E6 was greatest among the controls with high HPV16 E6 seroreactivity; 
46.7%.  Of the 5 HPV16 proteins evaluated, seroreactivity against HPV16 L1 was most common 
(n=5 out of 15, 33.3%).  Controls with high HPV16 E6 seroreactivity were also more likely than 
HPV16 E6 seronegative controls to be seroreactive against all HPV16 proteins with the 
exception of E7, however only HPV16 L1 (OR 4.3, 95% CI: 1.1-13.8) and E2 (OR 7.7, 95% CI: 
1.4-29.1) reached statistical significance.  High HPV16 E6 seroreactivity was also significantly 
associated with seroreactivity against multiple HPV16 proteins; OR 25.3 (95% CI: 2.6-119.6) for 
seroreactivity against 3 HPV16 proteins in addition to E6, although in absolute terms, 
seroreactivity against multiple HPV16 proteins was rare (4 of 4666; 0.08%). 
Seroreactivity against E6 proteins from non-HPV16 types was less common; 7.9% of HPV16 E6 
seronegative controls were seroreactive against any non-HPV16 type compared to approximately 
20% among both moderate and high HPV16 E6 seroreactive controls.  Only seroreactivity for 
HPV33 E6 was significantly associated with high HPV16 E6 seroreactivity; OR 17.7 (95% CI: 
1.9-81.8, Table 4). 
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DISCUSSION 
In this large descriptive epidemiological analysis of more than 4,000 pooled controls from 
several studies of HPV seroreactivity and HPV-associated cancer (23-25), HPV16 E6 
seropositive controls were rare (<1%), particularly those with high HPV16 E6 seroreactivity 
(0.3%).  Further, of the determinants of HPV16 seropositivity evaluated, significant associations 
were observed only among controls with high HPV16 E6 seroreactivity.  Of the demographic 
risk factors assessed, none were predictors of HPV16 E6 seropositivity except for former 
smoking.  Of the serologic determinants assessed, seroreactivity against other HPV16 proteins 
was common among all controls and was greatest among controls with high HPV16 E6 
seroreactivity (47%).  A marker of cumulative lifetime HPV16 exposure, HPV16 L1 
seropositivity (5 out of 15; 33.3%) was most commonly detected among high HPV16 E6 
seroreactive controls compared to the other 4 HPV16 proteins tested.  High HPV16 E6 
seroreactivity was significantly associated with seroreactivity against HPV16 L1 (OR 4.8, 95% 
CI: 1.3-15.4), E2 (OR 7.7, 95% CI: 1.4-29.1) and multiple HPV16 proteins (OR 25.3, 95% CI: 
2.6-119.6 for seroreactivity against any 3 HPV16 proteins in addition to E6).  Seropositivity for  
any non-HPV16 E6 proteins was less common; 8% among HPV16 E6 seronegative controls and 
approximately 20% among controls with both moderate and high HPV16 E6 seroreactivity.  
Only  HPV33 E6 seroreactivity was significantly associated with high HPV16 E6 seroreactivity; 
OR 17.7 (95% CI: 1.9-81.8), however due to its high sequence homology with the E6 protein of 
HPV16, this is finding may be the result of antibody cross-reactivity (35).   
Theoretically, individuals without an underlying HPV-driven cancer would not be expected to 
have antibodies against the HPV16 oncoproteins.  One potential explanation for the small 
percentage of controls with seroreactivity against HPV16 E6 may be due to potential laboratory 
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error or sample misclassification.  Therefore, the 15 strongly HPV16 E6 seroreactive controls 
identified may reflect the error rates within these large epidemiological studies.  Alternatively, 
the HPV16 E6 seroreactive controls identified in our study may be harboring a yet to be 
diagnosed cancer or precancer.  Recent findings have suggested that induction of HPV-specific 
antibodies, most notably HPV16 E6 antibodies, may be a response to an underlying HPV-driven 
neoplastic process that may take years to manifest into a diagnosable cancer (25).  Studies 
conducted at the time of diagnosis have shown that the presence of detectable HPV16-specific 
antibodies in diagnostic serum is highly sensitive for HPV-driven head and neck squamous cell 
carcinomas (36).  A large proportion (7 out of 15) of controls with high HPV16 E6 seroreactivity 
was also seroreactive against at least one other HPV16 protein in addition to HPV16 E6.  
However, of all HPV16 proteins, a recent prospective study showed that seroreactivity against 
HPV16 E6 is the most strongly associated with development of oropharyngeal cancer; OR 274 
(95% CI: 110-681).  Of note, all the HPV16 E6 seropositive oropharyngeal cancer cases 
identified in the previous study had HPV16 E6 MFI values greater than 1,000 and therefore 
would have been classified as having high seroreactivity in this current analysis (25).  Taken 
together, these findings raise the possibility that the HPV16 E6 seropositive controls described in 
this study may be on the path to developing an HPV-driven cancer or precancer that, as follow-
up accrues over time may eventually be diagnosed.  Updated record linkage of the EPIC head 
and neck cancer study (25) revealed that one HPV16 E6 seropositive control was subsequently 
diagnosed with invasive anal cancer, however, additional follow-up time is needed to fully 
investigate this possibility.  
Therefore, an important limitation of this study is that we are unable to extend follow-up to 
further ascertain the health status of the HPV16 E6 seropositive controls.  For the cohort studies 
14 
 
(EPIC and PLCO), we will continue to monitor record linkage updates and investigate this 
question accordingly; for the ARCAGE case-control studies, no additional follow-up will 
become available. Additionally, controls in this analysis were initially matched to cases, 
therefore skewing their distribution of certain variables, such as age and gender, towards that of 
cases.  For the case-control studies, controls were recruited only when they were eligible based 
on a list of non-chronic diseases unrelated to smoking and alcohol.  While this does not 
jeopardize the validity of our findings, it limits their generalizability.  There may have also been 
some minor misclassification in terms of smoking status and alcohol consumption due to the 
differences between studies in how these variables were ascertained on the questionnaires.  
Additionally, we do not have information regarding other covariates such as sexual behavior, and 
host immunogenetics, which may have been potentially helpful in explaining why some 
individuals develop these antibodies.  Finally, even with over 4,000 pooled controls, we were 
still limited by power given that our outcome was so rare.   
Due to the high specificity of the HPV16 E6 marker (25), HPV16 E6 antibody testing may have 
the potential to be further developed into a screening tool for identifying individuals at high-risk 
for oropharyngeal cancer.  Characterization of HPV16 E6 seropositivity within individuals 
without diagnosed cancer has important implications in terms of determining the utility of this 
marker as a screening tool.  Future prospective studies should aim to determine the positive 
predictive value of HPV16 E6 positivity for the diagnosis of oropharyngeal cancer.  
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Table 1: Participant characteristics overall and by study  
 
 
All Studies  
 
ARCAGE 
 
EPIC 
 
PLCO 
Characteristics N= 4666   N= 1425   N= 2317   N= 924 
 
N % 
 
N % 
 
N % 
 
N % 
Gender 
           Male  2972 63.7% 
 
1059 74.3% 
 
1165 50.3% 
 
748 81.0% 
Female 1694 36.3% 
 
366 25.7% 
 
1152 49.7% 
 
176 19.0% 
            Age 
           ≤60 2782 59.6% 
 
742 52.1% 
 
1726 74.5% 
 
314 34.0% 
61-70 1436 30.8% 
 
417 29.3% 
 
504 21.8% 
 
515 55.7% 
>70 448 9.6% 
 
266 18.7% 
 
87 3.8% 
 
95 10.3% 
            Region of Origin
1
 
               Eastern Europe 185 4.0% 
 
185 13.0% 
 
0 0.0% 
 
0 0.0% 
Northern Europe 1430 30.6% 296 20.8% 1134 48.9% 0 0.0% 
Southern Europe 1324 28.4%  757 53.1%  567 24.5%  0 0.0% 
Western Europe 803 17.2%  187 13.1%  616 26.6%  0 0.0% 
United States 924 19.8%  0 0.0%  0 0.0%  924 100.0% 
            
Smoking
2
 
           Never 1770 37.9% 
 
516 36.2% 
 
1040 44.9% 
 
214 23.2% 
Former 1614 34.6% 
 
506 35.5% 
 
718 31.0% 
 
390 42.2% 
Current 1242 26.6% 
 
403 28.3% 
 
519 22.4% 
 
320 34.6% 
          
  
Alcohol Consumption
2
 
          Never 475 10.2% 
 
172 12.1% 
 
148 6.4% 
 
155 16.8% 
Ever 3745 80.3% 
 
1252 87.9% 
 
1782 76.9% 
 
711 76.9% 
               
Abbreviations: European Prospective Investigation Into Cancer and Nutrition (EPIC); Alcohol-Related Cancers and 
Genetic Susceptibility in Europe (ARCAGE); Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial 
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(PLCO); mean fluorescence intensity (MFI) 
1
Northern Europe includes: Denmark, Great Britain, Ireland, Norway and Sweden 
Southern Europe includes: Croatia, Greece, Italy and Spain 
Western Europe includes: France, Germany and The Netherlands 
Eastern Europe includes: Czech Republic/Slovakia 
2
Columns do not add to total due to missing data 
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Table 2: Univariate Analysis of Demographic Characteristics and HPV16 E6 Seropositivity Among Controls 
        
 
   
HPV16 E6 Seropositive  
 
Total 
 
Moderate 
 
High  
Characteristics N= 4666   N= 17 OR (95% CI)   N= 15 OR (95% CI)  
 
N  
 
N (%) 
  
N (%) 
 
 
Study 
       
 
    All 4666 
 
17 (0.4) - 
 
15 (0.3) -  
    ARCAGE 1425 
 
5 (0.4) - 
 
6 (0.4) -  
    EPIC 2317 
 
9 (0.4) - 
 
4 (0.2) -  
    PLCO 924 
 
3 (0.3) - 
 
5 (0.5) -  
        
 
Gender 
       
 
    Male  2972 
 
11 (0.4) Ref 
 
10 (0.3) Ref  
    Female 1694 
 
6 (0.4) 1.0 (0.3-2.8) 
 
5 (0.3) 0.9 (0.2-2.8)  
        
 
Age 
       
 
    ≤60 2782 
 
9 (0.3) Ref 
 
9 (0.3) Ref  
    61-70 1436 
 
6 (0.4) 1.3 (0.4-4.1) 
 
5 (0.3) 1.1 (0.3-3.6)  
    >70 448 
 
2 (0.4) 1.4 (0.1-6.7) 
 
1 (0.2) 0.7 (0.0-5.0)  
       
 
 
Region of Origin
1
 
      
 
    Northern Europe 1430 
 
3 (0.2) Ref 
 
4 (0.3) Ref  
    Southern Europe 1324 
 
6 (0.5) 2.2 (0.5-13.4) 
 
3 (0.2) 0.8 (0.1-4.8)  
    Eastern Europe 185 
 
1 (0.5) 2.6 (0.0-32.3) 
 
0 (0.0) -  
    Western Europe 803 
 
4 (0.5) 2.4 (0.4-16.3) 
 
3 (0.4) 1.3 (0.2-7.9)  
    United States 924 
 
3 (0.3) 1.6 (0.2-11.6) 
 
5 (0.5) 1.9 (0.4-9.8)  
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Smoking
2
 
       
 
    Never 1770 
 
9 (0.5) Ref 
 
2 (0.1) Ref  
    Former 1614 
 
4 (0.2) 0.5 (0.1-1.8) 
 
10 (0.6) 5.5 (1.2-51.8)  
    Current 1242 
 
4 (0.3) 0.6 (0.1-2.3) 
 
3 (0.2) 2.1 (0.2-25.7)  
        
 
Alcohol Consumption
2
 
      
 
    Never 475 
 
2 (0.4) 1.0 (0.1-4.5) 
 
0 (0.0) N/E  
    Ever 3745 
 
15 (0.4) Ref 
 
12 (0.3) Ref  
         
Abbreviations: European Prospective Investigation Into Cancer and Nutrition (EPIC); Alcohol-Related Cancers and Genetic 
Susceptibility in Europe (ARCAGE); Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO); Not 
Estimateable (N/E) 
1
Northern Europe includes: Denmark, Great Britain, Ireland, Norway and Sweden 
Southern Europe includes: Croatia, Greece, Italy and Spain 
Western Europe include: France, Germany and The Netherlands 
Eastern Europe includes: Czech Republic/Slovakia 
2
Columns do not add to total due to missing data  
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Table 3: Association of HPV16 L1, E1, E2, E4 and E7 Seropositivity with Moderate and High HPV16 E6 Seroreactivity Among Controls 
    
 
HPV16 E6 Seronegative 
 
HPV16 E6 Seropositive 
 
 
 
 Moderate    High                                                                          
HPV16 Proteins Total No. Positive (%) OR 
 
Total No. Positive (%) OR (95%CI) 
 
Total No. Positive (%) OR (95%CI) 
Any
1
 4634 1245 (27.9) Ref  17 5 (29.4) 1.1 (0.3-3.5)  15 7 (46.7) 2.4 (0.7-7.5) 
HPV16 L1 4634 484 (10.4) Ref 
 
17 1 (5.9) 0.5 (0.0-3.5) 
 
15 5 (33.3) 4.3 (1.1-13.8) 
HPV16 E1 4632 155 (3.3) Ref 
 
17 0 (0.0) - 
 
15 1 (6.7) 2.1 (0.0-13.7) 
HPV16 E2 4634 145 (3.1) Ref 
 
17 1 (5.9) 1.9 (0.0-12.6) 
 
15 3 (20.0) 7.7 (1.4-29.1) 
HPV16 E4
2
 3718 367 (9.9) Ref 
 
14 3 (21.4) 2.5 (0.4-9.5) 
 
10 2 (20.0) 2.3 (0.2-11.5) 
HPV16 E7 4634 345 (7.4) Ref 
 
17 1 (5.9) 0.8 (0.0-5.0) 
 
15 1 (6.7) 0.9 (0.0-5.9) 
Positive for any 2
1
 4634 221 (4.8) Ref 
 
17 1 (5.9) 1.2 (0.0-8.1) 
 
15 2 (13.3) 3.1 (0.3-13.7) 
Positive for any 3
1
 4634 28 (0.6) Ref 
 
17 0 (0.0) - 
 
15 2 (13.3) 25.3 (2.6-119.6) 
Positive for any 4
1
 4634 2 (0.0) Ref 
 
17 0 (0.0) - 
 
15 0 (0.0) - 
Positive for any 5
1
 4634 0 (0.0) Ref 
 
17 0 (0.0) - 
 
15 0 (0.0) - 
            1
In addition to HPV16 E6 
2
Seroreactivity against HPV16 E4 was not assessed in PLCO 
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Table 4: Association of non-HPV16 Type E6 Seropositivity with Moderate and High HPV16 E6 Seroreactivity Among Controls 
    
 
HPV16 E6 Seronegative 
 
HPV16 E6 Seropositive 
 
 
 
Moderate 
 
High 
HPV E6 Proteins Total No. Positive (%) OR   Total No. Positive (%) OR (95% CI)   Total No. Positive (%) OR (95% CI) 
Any 4634 368 (7.9) Ref  17 4 (23.5) 3.6 (0.8-11.6)  15 3 (20.0) 2.9 (0.5-10.8) 
HPV6 4634 26 (0.6) Ref 
 
17 1 (5.9) 11.1 (0.3-76.6) 
 
15 0 - 
HPV11 4634 90 (1.9) Ref 
 
17 0 - 
 
15 1 (6.7) 3.6 (0.1-24.2) 
HPV18 4634 56 (1.2) Ref 
 
17 1 (5.9) 5.1 (0.1-34.0) 
 
15 0 - 
HPV31 4634 85 (1.8) Ref 
 
17 1 (5.9) 3.3 (0.1-22.0) 
 
15 0 - 
HPV33 4634 40 (0.9) Ref 
 
17 0 - 
 
15 2 (13.3) 17.7 (1.9-81.8) 
HPV45 4634 65 (1.4) Ref 
 
17 0 - 
 
15 0 - 
HPV52
1
 3920 48 (1.2) Ref 
 
14 1 (7.1) 6.2 (0.1-42.9) 
 
14 0 - 
          
1
Seroreactivity against the E6 protein of HPV52 was not determined in the EPIC anogenital study 
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Supplemental Table 1: Study-specific definitions for categorization of tobacco and alcohol use. 
 Smoking  Alcohol Use 
Study Current Never Former  Ever Never 
EPIC Individuals who ever 
reported smoking a 
cigarette, pipe or cigar 
in their lifetime 
Individuals who never 
smoked a cigarette, 
pipe or cigar in their 
lifetime 
Individuals who 
had smoked in the 
past, but reported 
not smoking 
currently 
 Individuals who have 
ever consumed an 
alcoholic beverage 
Individuals who have 
never consumed an 
alcoholic beverage 
PLCO Individuals who ever 
smoked cigarettes 
regularly for 6 months 
or longer 
Individuals who never 
smoked a cigarette, 
pipe or cigar in their 
lifetime 
Individuals who 
smoked in the past, 
but reported not 
smoking currently 
 Individuals who have 
ever consumed an 
alcoholic beverage 
Individuals who have 
never consumed an 
alcoholic beverage 
ARCAGE Individuals who 
reported smoking any 
tobacco product at least 
once a week for a year 
Individuals who 
reported never using 
tobacco in their lifetime 
or smoking less than 
once a week for a year 
Individuals who 
reported having 
quit smoking for at 
least 12 months 
 Individuals who ever 
reported consuming any 
alcoholic beverage 
Individuals who had 
never consumed any 
alcoholic beverages in 
their lifetime or who 
had not consumed 
alcohol within the past 
12 months 
Abbreviations: European Prospective Investigation Into Cancer and Nutrition (EPIC); Alcohol-Related Cancers and Genetic Susceptibility in 
Europe (ARCAGE); Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) 
 
